ascopubs.org

Factors influencing surgical treatment of adenoid cystic carcinoma of the head and neck: A National Cancer Database analysis.

Pilot study evaluating the addition of cemiplimab in BRAF-mutant anaplastic thyroid cancer after progression on dabrafenib and trametinib. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
The Manila Times

Day One Completes Acquisition of Mersana Therapeutics

Acquisition expands Day One’s pipeline with clinical-stage antibody drug conjugate (ADC) emiltatug ledadotin (Emi-Le) ...
BioWorld

Rgenta’s RGT-61159 cleared by FDA for first-in-human trial in adenoid cystic carcinoma and colorectal cancer

Rgenta Therapeutics Inc. has received IND clearance by the FDA for RGT-61159, which is being developed for adenoid cystic carcinoma, colorectal cancer and other solid tumors, as well as acute myeloid ...
EurekAlert!

Treatment strategies for adenoid cystic carcinoma of the head and neck

“Proton therapy [...] seems to have decisive advantages with regard to the long-term survival of [adenoid cystic carcinoma] [...]” In general, tumors originating from the minor salivary glands often ...
WGN Radio

Rgenta Therapeutics Announces First Patients Dosed in Phase 1a/b Clinical Trial of RGT-61159, an Oral Small Molecule Targeting MYB, in Adenoid Cystic Carcinoma (ACC) and ...

First-in-human study in patients with solid tumors initially evaluating the safety, tolerability pharmacokinetics and target engagement of RGT-61159 WOBURN, Mass., Oct. 8, 2024 /PRNewswire/ -- Rgenta ...